Clinical studies of biapenem, a new carbapenem antibiotic, in urogenital infection

Clinical studies were carr+ied out to assess the effect and safety of biapenem (BIPM) in urogenital field infections, and the results were as follows. In the laboratory study, the MIC₅₀ of BIPM against 77 clinical strains of Pseudornonas aeruginosa isolated from c-UTI in 1992/1993 was 1.56μg/ml, which was lower for 2 tubes than imipenem. In the clinical study, thirty-nine patients, including 28 cases of chronic complicated UTI, 3 of acute uncomplicated pyelonephritis and 8 of acute bacterial prostatitis, were treated at doses of 300∼1200mg a day for 2∼10 days. In complicated UTI, the clinical efficacy was excellent or moderate in 19 of 21 patients (90%). For the bacteriological response, in 19 strains of 8 species of GPC, and 17 strains of 8 species of GNB, 94% of bacteria were eradicated after treatment. In uncomplicated UTI and acute bacterial prostatitis, the clinical efficacy was 100%. No side effects were observed. In abnormal laboratory findings, mild transient elevation of GPT in 3 cases and decrease of leucocytes in 1 case were observed.